| Sanz G, Fuster V, Guzmán L, Guglietta A, Arnáiz JA, Martínez F, Sarria A, Roncaglioni MC, Taubert K. The Fixed-dose Combination Drug for Secondary Cardiovascular Prevention project: Improving equitable access and adherence to secondary cardiovascular prevention with a fixed-dose combination drug. Study design and objectives. Am Heart J (2011) 162:811-817.e1 |
| Fuster V, Kelly BB, Vedanthan R. Promoting global cardiovascular health: moving forward. Circulation (2011) 123:1671-8 |
| Soderquest K, Powell N, Luci C, van Rooijen N, Hidalgo A, Geissmann F, Walzer T, Lord GM, Martín-Fontecha A. Monocytes control natural killer cell differentiation to effector phenotypes. Blood (2011) 117:4511-8 |
| Garaulet M, Sánchez-Moreno C, Smith CE, Lee YC, Nicolás F, Ordovás JM. Ghrelin, Sleep Reduction and Evening Preference: Relationships to CLOCK 3111 T/C SNP and Weight Loss. Plos One (2011) 6:e17435 |
| Fuster V, Sweeny JM. Aspirin: a historical and contemporary therapeutic overview. Circulation (2011) 123:768-78 |
| Zaragoza C, Gomez-Guerrero C, Martin-Ventura JL, Blanco-Colio L, Lavin B, Mallavia B, Tarin C, Mas S, Ortiz A and Egido J. Animal models of cardiovascular diseases. J Biomed Biotechnol (2011) 2011:497841 |
| Franco M, Cooper RS, Bilal U, Fuster V. Challenges and opportunities for cardiovascular disease prevention. Am J Med (2011) 124:95-102 |
| Ibanez B, Fuster V, Jiménez-Borreguero J, Badimon JJ. Lethal myocardial reperfusion injury: A necessary evil?. Int J Cardiol (2011) 151:3-11 |
| Mearns BM, Fuster V. Highlight dementia risk to reduce CVD. Nat Rev Cardiol (2010) 7:237 |
| Sanz J, Fuster V. Update in Cardiology. Ann Intern Med (2010) 152:786-91 |

The ACI department is dedicated to developing noninvasive technologies for molecular-resolution imaging. Through these technologies, vulnerable plaques can be identified and characterized, providing invaluable information on the underlying molecular mechanisms of disease and leading to tools for accurate diagnosis and targeted drug delivery.